Eve Combes
Montpellier, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.
Journal: Journal for immunotherapy of cancer
Published: March 01, 2025
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry.
Journal: International journal of molecular sciences
Published: May 02, 2022
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1.
Journal: Cancers
Published: May 25, 2021
Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.
Journal: Cancer research
Published: September 11, 2018
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Journal: BMC cancer
Published: December 13, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 22, 2017
FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
Journal: British journal of cancer
Published: July 08, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026